Durable Reduction in MRI Disease Activity and Slowing of Brain Volume Loss With Alemtuzumab in Patients With Active RRMS: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study)

Details

Database :

OpenAIRE

Accession number :

edsair.doi...........675e85af9d647b99b21376dcaab5c6e4

Full Text :

https://doi.org/10.26226/morressier.59a3edacd462b8028d895458